FDA: Dialysis Tubing Sets Recalled Due to Dislodging, Updated Instructions
Summary
The FDA is alerting healthcare providers about a recall of Vantive dialysis tubing sets due to potential dislodging of the deaeration chamber. Updated instructions for use have been issued to mitigate risks, emphasizing monitoring the chamber during therapy. This is a correction and does not involve removing the devices from use or sale.
What changed
The FDA has issued an updated safety alert regarding Vantive dialysis tubing sets (Prismaflex and Oxiris) due to the risk of the deaeration chamber dislodging during therapy, which could lead to temporary or reversible health problems. While the affected products and recommendations remain unchanged, the alert clarifies that this is a correction involving updated use instructions, not a removal from the market. Specific affected product codes and lot numbers are identified.
Healthcare providers using these devices must monitor the deaeration chamber during therapy to ensure it remains upright. If an "Air in Blood" alarm occurs, providers should check for dislodgement, air, or clots and follow the operator's manual instructions accordingly. The manufacturer, Vantive, has provided a letter to customers detailing these steps. Facilities that distributed the product further should forward this communication to downstream users.
What to do next
- Monitor deaeration chamber during therapy to ensure it remains upright.
- Follow updated instructions for "Air in Blood" alarms, checking for dislodgement, air, or clots.
- Forward communication to any downstream distributors or departments.
Source document (simplified)
The FDA has since determined that this device may cause temporary or reversible health problems, or—though unlikely—serious health problems. *The affected products and recommendations for what to do with the devices below have not changed. This*** recall involves updating instructions for affected devices, and does not involve removing them from where they are used or sold.
Affected Product
The FDA is aware that Vantive has issued a letter informing affected customers that Prismaflex Control Units have updated use instructions.
Affected devices:
| Device Name | Product Code | UDI-DI | Lot Numbers |
| --- | --- | --- | --- |
| PRISMAFLEX ST100 SET US | 107636US | 00085412954073 | All lots including and manufactured after 24G0072 |
| PRISMAFLEX ST150 SET US | 107640US | 00085412917696 | All lots including and manufactured after 24F0085 |
| OXIRIS SET | 112016 | 07332414102234 | All lots including and manufactured after 24G0041Z |
| PRIMSAFLEX M100 SET | 106697 | 07332414064556 | All lots including and manufactured after 24F0077CA |
| PRISMAFLEX M150 SET | 109990 | 07332414090005 | All lots including and manufactured after 24F0100CA |
| PRISMAFLEX HF1000 SET | 107140 | 07332414069254 | All lots including and manufactured after 24G0034CA |
| PRISMAFLEX HF1400 SET | 107142 | 07332414069315 | All lots including and manufactured after 24F0094CA |
| PRISMAFLEX TPE2000 SET | 114093 | 07332414111038 | All lots including and manufactured after 24J0106 |
What to Do
When using affected products, monitor the deaeration chamber during therapy to ensure it remains in an upright position within the holder.
On January 6, Vantive sent all affected customers a letter recommending the following actions:
- You may continue to perform therapy using affected Prismaflex sets. Please monitor the deaeration chamber during therapy to ensure it remains in an upright position within the holder.
- Vantive is aware of customers who have experienced this issue and attempted to further secure the deaeration chamber in an upright position. If attempting to secure the deaeration chamber in an upright position, please consider the following:
- Ensure there are no kinks in the tubing and that the deaeration chamber remains visible.
- If the Prismaflex Control Unit issues an “Air in Blood” alarm, check if air is present. If there is no air present, check if the deaeration chamber is dislodged from the holder and ensure there are no clots present.
- If no dislodgement, please follow the operator’s manual instructions for “Air in Blood” alarm.
- In case of dislodgement with clotting, follow the associated instructions within the Prismaflex Control Unit operator’s manual to stop the therapy and replace the set.
- Only in case of dislodgement without clotting or any other alarms, if the chamber is secured in an upright position, follow the associated instructions within the Prismaflex Control Unit operator’s manual to proceed with treatment.
- If you purchased this product from a distributor, please note that responding using the Vantive Customer Reply Form is not applicable. If a response is requested by your distributor or wholesaler, please respond to the supplier according to their instructions.
- If you distributed this product to other facilities or departments within your institution, please forward a copy of this communication to them.
Reason for Correction
Vantive stated that Prismaflex Set deaeration chambers may dislodge from the Prismaflex Control Unit, as shown above. This issue does not affect PrisMax Control Units, as these devices have a different deaeration chamber holder design.
A dislodged deaeration chamber may lead to an “Air in Blood” alarm on the Prismaflex Control Unit. The alarm may occur during the priming phase prior to initiating therapy, or during therapy. This may result in delays or interruptions to therapy and blood loss due to clotting and failure to return blood manually.
As of December 17, Vantive has not reported any serious injuries or deaths associated with this issue.
Device Use
Different Prismaflex sets are used with PrismaFlex control units or PrisMax control units in providing continuous fluid management and renal replacement therapies, blood purification, or therapeutic plasma exchange.
Additional FDA Resources
Contact Information
Customers in the U.S. with adverse reactions, quality problems, or questions about this recall should contact Vantive at 833-542-2778.
Unique Device Identifier (UDI)
The unique device identifier (UDI) helps identify individual medical devices sold in the United States from distribution to use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified more quickly, and as a result, problems potentially resolved more quickly.
- How do I recognize a UDI on a label?
- AccessGUDID database - Identify Your Medical Device
- Benefits of a UDI System
How do I report a problem?
Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
Timeline of Communication Updates
| Date | Actions |
| --- | --- |
| 03/16/2026 | The FDA updated this communication to inform the public that this issue has been classified as a Class II Recall. |
| 01/14/2026 | The FDA issued an Early Alert communication to notify the public of a potentially high-risk device issue. |
- ## Content current as of:
03/16/2026
Regulated Product(s)
- Medical Devices
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when FDA MedWatch Safety Alerts publishes new changes.